Merck's lambrolizumab wins breakthrough status for melanoma

04/25/2013 | Fox Business

The FDA granted breakthrough therapy status to Merck & Co.'s experimental antibody drug lambrolizumab as a treatment for advanced melanoma. Lambrolizumab, which targets the programmed death receptor, is also being evaluated as a treatment for nonsmall-cell lung cancer.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI